Co-Authors
This is a "connection" page, showing publications co-authored by MOTHAFFAR RIMAWI and C OSBORNE.
Connection Strength
1.025
-
Targeting HER2 for the treatment of breast cancer. Annu Rev Med. 2015; 66:111-28.
Score: 0.471
-
Breast Cancer: Blocking both driver and escape pathways improves outcomes. Nat Rev Clin Oncol. 2012 Feb 14; 9(3):133-4.
Score: 0.386
-
Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators. Cancer Chemother Pharmacol. 2005 Nov; 56 Suppl 1:10-20.
Score: 0.062
-
A CTC-Cluster-Specific Signature Derived from OMICS Analysis of Patient-Derived Xenograft Tumors Predicts Outcomes in Basal-Like Breast Cancer. J Clin Med. 2019 10 24; 8(11).
Score: 0.041
-
Circulating and disseminated tumor cells from breast cancer patient-derived xenograft-bearing mice as a novel model to study metastasis. Breast Cancer Res. 2015 Jan 09; 17:3.
Score: 0.029
-
Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res. 2008 Feb 01; 68(3):826-33.
Score: 0.018
-
Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer. Cancer Res. 2006 Aug 15; 66(16):8266-73.
Score: 0.016